Navigation Links
XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow

XenaCare Holdings has announced that it will be supporting the rapidly-growing network of retailers carrying its over-the-counter (OTC) pain reliever, Cobroxin, by expanding its multimillion dollar national marketing campaign to include direct response mailings, television commercials, national sponsorships, and additional print advertising.

Delray Beach, FL (Vocus) January 19, 2010 -- XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it is expanding its multimillion dollar national advertising campaign to include direct response mailings, television commercials, national sponsorships and additional print advertising to support the rapidly growing network of retailers carrying Cobroxin, an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain.

“We introduced Cobroxin, through e-commerce websites, during the last quarter of 2009. This quarter, we are pleased to report that the product has been reviewed and accepted by 40% of the 105,000 retail stores selling healthcare products across the United States, as reported by Chain Drug Review magazine,” said Frank Rizzo, President and CEO of XenaCare Holdings. “We anticipate the average retailer will place an opening order of $80 per store location. With analgesic products producing up to 21 inventory turnovers per year, the upside potential is dramatic and very exciting for Cobroxin,” he concluded.

In addition to its current print advertising campaign, XenaCare Holdings has purchased advertising in several men’s, women’s and specialty magazines. These advertisements are scheduled to debut in February and are projected to generate approximately 108 million reader impressions over the next 3 months. Cobroxin will also be featured in several printed retail catalogs, reaching approximately 18 million households throughout the United States.

Recently, the Company became a National Proud Sponsor of the Arthritis Foundation. This sponsorship allows XenaCare Holdings to use the Foundation’s logo on packaging, websites, print advertisements, retail catalogs and when sending out direct mailers to 100,000 Arthritis Foundation members. XenaCare Holdings plans to continue strengthening its relationship with the Arthritis Foundation and supporting the Foundation’s mission throughout 2010.

In October, the Company announced that it would be advertising in the official annual publication of NASCAR, which reaches approximately 8,000,000 attendees, as well as the NFL Alumni Guide Program and Yearbook. The Company recently expanded this targeted outreach to include advertising in the upcoming 2010 Super Bowl XLIV program guide and the 2010 NBA All-Star Game program guide.

Cobroxin will also be featured in direct response advertising with 60 second spots beginning in late January 2010.

Finally, XenaCare Holdings has begun production for a series of television commercials scheduled to air in April. Additional details regarding these commercials will be released in the near-term.

Cobroxin is currently available to independent pharmacy owners through the Chain Drug Marketing Association (CDMA), one of the largest pharmacy organizations representing more than 6,000 retail outlets throughout 32 states. Additionally, Cobroxin will be sold through most mass market retailers, including major drugstore chains and supermarkets, as well as online at,, and

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. The drug is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:

  • All Natural
  • Non-Addictive
  • Non-Narcotic
  • Non-Opiate
  • More Potent than Morphine
  • Long Lasting
XenaCare Holdings was granted the exclusive license by Nutra Pharma Corporation (OTCBB:NPHC) to market and distribute Cobroxin within the United States.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.

Cautionary Note Concerning Forward Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans for specific advertising and marketing campaigns supporting Cobroxin are forward looking statement and subject to change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation
2. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
3. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
4. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
5. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
6. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
7. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
8. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
9. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results
10. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
11. HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation
Post Your Comments:
Related Image:
XenaCare Holdings Announces Expansion of  National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New ... is so important to this key industry segment, Regis Technologies has decided to sponsor ... December 4th at 11am EST. , Federal law does not allow new drugs to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced ... a Healthcare IT consulting, development and support company. The purchase will expand the ... within DataTrade to extend the services currently provided by Healthjump. , ...
(Date:11/30/2015)... ... , ... GKhair & Tibolli team members and artists were excited and proud ... 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. The ... of the line fashion journalists. The San Juan Beauty Show carries immense credibility among ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... for healthcare professionals worldwide today released the results of a survey of educational ... East and Africa found a growing global demand for high quality online and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... YORK , Nov. 30, 2015 Cumberland Pharmaceuticals ... will present live at on December 3, 2015. ... --> TIME: 3:15p.m. ET LINK: ... ET LINK: --> ... online event where investors are invited to ask the company ...
(Date:11/30/2015)... Nov. 30, 2015 Varian Medical Systems (NYSE: VAR ... educational partnership with Apollo Hospitals Group, the largest hospital chain in ... help train radiation technologists in the country. The MoU was signed ... Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its Access ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
Breaking Medicine Technology: